Loading organizations...
§ Private Profile · Basel, Basel-Stadt, Switzerland
Biotechnology company developing therapies that selectively modulate mast cells for allergies and inflammatory diseases.
Allegria Therapeutics is a Basel, Switzerland-based biotechnology company that develops proprietary therapeutic approaches targeting biological molecules to selectively modulate mast cells for treating allergies and inflammatory diseases. The enterprise was founded in 2023 by chief executive officer Maria van Dongen and founding investor Forty51 Ventures to address unmet medical needs in immunology. To advance its pipeline, the seed-stage firm raised over eight million dollars in venture capital, comprising an initial seed round in 2024 and a five million dollar extension in December 2025. This recent financing was backed by a prominent syndicate of life sciences investors, featuring lead backer ALK-Abelló alongside HighLight Capital and the Lichtsteiner Foundation. Furthermore, the company collaborates with academic partners at Charité in Berlin and the Medical University of Vienna, while recently adding Peter Sejer Andersen to its board of directors.
Allegria Therapeutics has raised $8.6M across 2 funding rounds.
Allegria Therapeutics has raised $8.6M in total across 2 funding rounds.
Allegria Therapeutics has raised $8.6M across 2 funding rounds. Most recently, it raised $5.1M Seed Extension in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 11, 2025 | $5.1M Seed Plus | Peter Sejer Andersen | Forty51 Ventures, Lichtsteiner Foundation | Announced |
| May 6, 2024 | $3.5M Seed | Forty51 Ventures | — | Announced |
Allegria Therapeutics has raised $8.6M in total across 2 funding rounds.
Allegria Therapeutics's investors include Peter Sejer Andersen, Forty51 Ventures, Lichtsteiner Foundation.